HY-P99152-1mg
|
MedChemexpress LLC
|
Mu romonab [CAS 140608-64-6]
|
|
COVID-19-immunoregulation
|
|
HY-P99152-10mg
|
MedChemexpress LLC
|
Mu romonab [CAS 140608-64-6]
|
|
COVID-19-immunoregulation
|
|
HY-P99152-5mg
|
MedChemexpress LLC
|
Mu romonab [CAS 140608-64-6]
|
|
COVID-19-immunoregulation
|
|
HY-42490-100mg
|
MedChemexpress LLC
|
N3-PEG3-CH2CH2COOH [CAS 1056024-94-2]
|
|
COVID-19-immunoregulation
|
|
HY-42490-50mg
|
MedChemexpress LLC
|
N3-PEG3-CH2CH2COOH [CAS 1056024-94-2]
|
|
COVID-19-immunoregulation
|
|
HY-108831-10mg
|
MedChemexpress LLC
|
Natalizumab [CAS 189261-10-7]
|
|
COVID-19-immunoregulation
|
|
HY-108831-25mg
|
MedChemexpress LLC
|
Natalizumab [CAS 189261-10-7]
|
|
COVID-19-immunoregulation
|
|
HY-108831-5mg
|
MedChemexpress LLC
|
Natalizumab [CAS 189261-10-7]
|
|
COVID-19-immunoregulation
|
|
HY-114816-100mg
|
MedChemexpress LLC
|
N-Butanoyl-L-homoserine lactone [CAS 67605-85-0]
|
|
COVID-19-immunoregulation
|
|
HY-114816-50mg
|
MedChemexpress LLC
|
N-Butanoyl-L-homoserine lactone [CAS 67605-85-0]
|
|
COVID-19-immunoregulation
|
|
HY-P99378-1mg
|
MedChemexpress LLC
|
Neihulizumab [CAS 2158362-38-8]
|
|
COVID-19-immunoregulation
|
|
HY-P99378-10mg
|
MedChemexpress LLC
|
Neihulizumab [CAS 2158362-38-8]
|
|
COVID-19-immunoregulation
|
|
HY-P99378-5mg
|
MedChemexpress LLC
|
Neihulizumab [CAS 2158362-38-8]
|
|
COVID-19-immunoregulation
|
|
HY-P99162-1mg
|
MedChemexpress LLC
|
Nemolizumab [CAS 1476039-58-3]
|
|
COVID-19-immunoregulation
|
|
HY-P99162-10mg
|
MedChemexpress LLC
|
Nemolizumab [CAS 1476039-58-3]
|
|
COVID-19-immunoregulation
|
|
HY-P99162-5mg
|
MedChemexpress LLC
|
Nemolizumab [CAS 1476039-58-3]
|
|
COVID-19-immunoregulation
|
|
HY-P99036-1mg
|
MedChemexpress LLC
|
Nesvacumab [CAS 1296818-77-3]
|
|
COVID-19-immunoregulation
|
|
HY-P99036-10mg
|
MedChemexpress LLC
|
Nesvacumab [CAS 1296818-77-3]
|
|
COVID-19-immunoregulation
|
|
HY-P99036-5mg
|
MedChemexpress LLC
|
Nesvacumab [CAS 1296818-77-3]
|
|
COVID-19-immunoregulation
|
|
HY-P99037-1mg
|
MedChemexpress LLC
|
Nipocalimab [CAS 2211985-36-1]
|
|
COVID-19-immunoregulation
|
|
HY-P99037-5mg
|
MedChemexpress LLC
|
Nipocalimab [CAS 2211985-36-1]
|
|
COVID-19-immunoregulation
|
|
HY-P9932-1mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
HY-P9932-10mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
HY-P9932-5mg
|
MedChemexpress LLC
|
Obiltoxaximab [CAS 1351337-07-9]
|
|
COVID-19-immunoregulation
|
|
HY-P99038-1mg
|
MedChemexpress LLC
|
Odronextamab [CAS 1801338-64-6]
|
|
COVID-19-immunoregulation
|
|